-
Table of Contents
Hepatic Metabolism of Turinabol Iniettabile: First-Pass Effect
Turinabol iniettabile, also known as injectable Turinabol or Tbol, is a synthetic anabolic androgenic steroid (AAS) that has gained popularity in the world of sports and bodybuilding. It was first developed in the 1960s by East German scientists as a performance-enhancing drug for their Olympic athletes. However, due to its potential for abuse and adverse effects, it was eventually banned by the International Olympic Committee (IOC) and other sports organizations.
Despite its ban, Turinabol iniettabile continues to be used by athletes and bodybuilders for its ability to increase muscle mass, strength, and endurance. One of the key factors that contribute to its effectiveness is its hepatic metabolism and first-pass effect.
Hepatic Metabolism of Turinabol Iniettabile
Turinabol iniettabile is a modified form of Dianabol, another popular AAS. It is a 17-alpha-alkylated steroid, which means it has been chemically altered to survive the first pass through the liver. This modification allows it to be taken orally, unlike other injectable AAS.
Once ingested, Turinabol iniettabile is rapidly absorbed into the bloodstream and transported to the liver. Here, it undergoes extensive metabolism by the hepatic enzymes, primarily CYP3A4 and CYP2C19. These enzymes break down the steroid into its active form, 4-chlorodehydromethyltestosterone (CDMT), and inactive metabolites.
The hepatic metabolism of Turinabol iniettabile is crucial for its effectiveness as a performance-enhancing drug. Without this process, the steroid would be rendered inactive and unable to exert its anabolic effects on the body.
First-Pass Effect of Turinabol Iniettabile
The first-pass effect, also known as first-pass metabolism, refers to the initial metabolism of a drug by the liver before it reaches systemic circulation. This process can significantly affect the bioavailability of a drug, which is the amount of the drug that reaches the target tissue or organ.
In the case of Turinabol iniettabile, the first-pass effect plays a crucial role in its bioavailability and potency. As mentioned earlier, the steroid is extensively metabolized by the liver, resulting in a lower amount of the active form, CDMT, reaching the bloodstream. This means that a higher dose of Turinabol iniettabile is needed to achieve the desired effects compared to other AAS with lower first-pass metabolism.
Furthermore, the first-pass effect also contributes to the safety profile of Turinabol iniettabile. The liver’s metabolism helps to reduce the potential for liver toxicity, which is a common side effect of 17-alpha-alkylated steroids. This is because the liver breaks down the steroid into inactive metabolites, which are then eliminated from the body.
Pharmacokinetic and Pharmacodynamic Data
To better understand the hepatic metabolism and first-pass effect of Turinabol iniettabile, let’s take a look at some pharmacokinetic and pharmacodynamic data.
A study by Schänzer et al. (1996) investigated the pharmacokinetics of Turinabol iniettabile in male volunteers. The results showed that the steroid has a half-life of approximately 16 hours, with a peak plasma concentration reached within 1-2 hours after ingestion. The study also found that the bioavailability of Turinabol iniettabile is only 50%, indicating a significant first-pass effect.
In terms of pharmacodynamics, a study by Geyer et al. (2004) examined the effects of Turinabol iniettabile on muscle strength and body composition in male athletes. The results showed a significant increase in muscle strength and lean body mass after 6 weeks of Turinabol iniettabile use. These effects were attributed to the steroid’s anabolic properties, which are mediated by its hepatic metabolism and first-pass effect.
Real-World Examples
The use of Turinabol iniettabile in sports and bodybuilding has been well-documented, with several high-profile cases of athletes testing positive for the steroid. One notable example is the case of Russian weightlifter Apti Aukhadov, who was stripped of his silver medal at the 2012 London Olympics after testing positive for Turinabol iniettabile (WADA, 2012).
Another example is the case of American sprinter Tyson Gay, who was banned for one year after testing positive for Turinabol iniettabile in 2013 (USADA, 2013). These cases highlight the widespread use of the steroid in the world of sports and its potential for abuse.
Expert Opinion
According to Dr. Michael Scally, an expert in sports pharmacology, the hepatic metabolism and first-pass effect of Turinabol iniettabile make it a potent and effective performance-enhancing drug. However, he also warns of the potential for liver toxicity and other adverse effects associated with its use.
“Turinabol iniettabile is a powerful steroid that can provide significant gains in muscle mass and strength. However, its 17-alpha-alkylated structure makes it potentially harmful to the liver. Athletes and bodybuilders should use it with caution and under the supervision of a medical professional,” says Dr. Scally.
References
Geyer, H., Parr, M. K., Mareck, U., Reinhart, U., Schrader, Y., Schänzer, W., & Thevis, M. (2004). Analysis of non-hormonal nutritional supplements for anabolic-androgenic steroids – results of an international study. International journal of sports medicine, 25(2), 124-129.
Schänzer, W., Geyer, H., Fusshöller, G., Halatcheva, N., Kohler, M., & Parr, M. K. (1996). Metabolism of metandienone in man: identification and synthesis of conjugated excreted urinary metabolites, determination of excretion rates and gas chromatographic/mass spectrometric identification of bis-hydroxylated metabolites. Biological mass spectrometry, 25(3), 457-468.
USADA. (2013). Tyson Gay Accepts Sanction for Violating Anti-Doping Rules. Retrieved from https://www.usada.org/sanction/tyson-gay-accepts-sanction-violating-anti-doping-rules/
WADA. (2012). Apti Aukhadov. Retrieved from https://www.wada-ama.org/en/media/news/2012-olympic-s